A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer

Full Title

Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer


In men with prostate cancer, it is often difficult to tell which drugs might be most effective against prostate cancer cells. The purpose of this study is to see how one drug, degarelix, affects the prostate gland.

Degarelix is used to treat prostate cancer by lowering the levels of cancer-fueling testosterone in the body. In this study, patients will take degarelix four or seven days before prostate cancer surgery. After doctors remove the prostate gland, it will be examined to see what effect degarelix has had on prostate cancer cells.

Doctors do not expect patients in this study to benefit directly from degarelix, since the prostate will be removed shortly afterward. Instead, doctors hope to better understand how degarelix works on prostate cancer cells and to use this information to develop additional prostate cancer treatments in the future.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have prostate cancer that has an intermediate or high risk of recurring and has not spread beyond the prostate.
  • Patients must be planning to have surgery to remove the prostate at Memorial Sloan-Kettering Cancer Center.
  • Patients’ cancers must not have been previously treated with other therapies (such as radiation or hormonal therapy).

For more information about this study and to inquire about eligibility, please contact Dr. Dana Rathkopf at 646-422-4379.